Santarus Sample Clauses

Santarus. Subject to Applicable Law, Santarus will implement reasonable safeguards consistent with those safeguards that it uses in relation to its own products so that Licensed Product is sold to customers for resale only outside of the GSK Territory and not for resale anywhere in the GSK Territory. If Santarus becomes aware that any of its customers has shipped Licensed Product into the GSK Territory, or has reason to believe that a customer intends to ship Licensed Product into the GSK Territory, Santarus, to the extent permitted by Applicable Law, will take Commercially Reasonable Efforts to cause such customer to cease such activities. Santarus shall, within thirty (30) days after learning that any Licensed Products sold by or under authority of Santarus under this Agreement have been sold, distributed or dispensed into of the GSK Territory, notify GSK in writing of all pertinent information relating to such occurrence and the actions Santarus plans to take in response thereto.
Sample 1Sample 2
AutoNDA by SimpleDocs
Santarus. Santarus shall maintain self insurance or comprehensive general liability insurance (“CGL”), including broad form contractual liability, in an amount of at least Twelve Million Dollars (U.S. $12,000,000) and product liability coverage in an amount of at least Fifteen Million U.S. Dollars (U.S. $15,000,000) for bodily injury and property damage. Santarus shall maintain such insurance during the Term and thereafter for a period of five (5) years. Santarus shall give GSK at least thirty (30) days notice of any cancellation or termination of such insurance. Santarus will furnish to GSK a certificate of insurance evidencing such coverage (or evidence reasonably acceptable to GSK of Santarus level of self-insurance) as of the Effective Date and upon reasonable request by GSK at any time thereafter.
Sample 1Sample 2
Santarus. Santarus warrants and represents to Schering that:
Sample 1
Santarus. Santarus shall maintain comprehensive general liability (CGL) insurance, including broad form contractual liability and product liability coverages, in an amount of at least [***] dollars ($[***]) for bodily injury and property damage. Santarus shall maintain such insurance during the term of this Agreement and thereafter for a period of [***] years. Schering shall be named as an additional insured under Santarus’ CGL policy. Upon request, Santarus shall provide Schering with a certificate of insurance as evidence of the requested coverages and shall give Schering at least thirty (30) days notice of any cancellation or termination of such insurance.
Sample 1
Santarus. Santarus represents and warrants to Co-Promotion Partner that (i) to the best of its knowledge, based on the knowledge of Santarus' personnel responsible for development of the Product(s), the data regarding the efficacy and safety of the Product(s) that is contained in Santarus' NDA and other regulatory filings submitted to the FDA in support of marketing approval of the Product(s) is complete and accurate in all materials respects, does not contain any misstatement of a material fact related to safety or efficacy nor omit to state any material fact in Santarus' possession related to safety or efficacy; (ii) as of the Effective Date, it has received no notice from a third party claiming any ownership interest in the patent rights covering the Product(s) (other than the ownership interest of the University of Missouri); (iii) as of the Effective Date, it is unaware of any third-party infringement of the Product(s) which would have a material adverse effect on the rights granted to Co-Promotion Partner hereunder; and (iv) the Product(s)' label and labeling and the related written sales, advertising, marketing, promotional and training materials provided to Co-Promotion Partner by Santarus shall comply with all applicable laws, rules and regulations.
Sample 1
Santarus. Santarus agrees that it will not sell or distribute PR Product in the Territory, except as set forth in this Section 2.2.3. Except as set forth in this Section 2.2.3, Santarus will not knowingly sell or otherwise offer PR Product to any Third Party that Santarus reasonably believes is going to sell such PR Product, directly or indirectly, in the Territory, unless mutually agreed in writing by both Parties. If Santarus becomes aware that any of its customers has shipped PR Product to the Territory or has reason to believe that a customer intends to ship PR Product to the Territory, it will review with GSK the level of sales of PR Products in such circumstances, and where the level of such sales exceeds that which occurs in the normal course of business, GSK and Santarus shall discuss the situation in good faith, with the objective to confirm that the tracking processes described in the letter agreement referenced in Section 2.2.2 are adequate in light of such sales and other related business considerations arising from such sales. It is acknowledged by the Parties that (i) certain sales of PR Products outside the Territory by Santarus to managed care organizations, group purchasing organizations, pharmacy benefit managers or similar purchasers or retailers (including, for example, [***]), or their Affiliates, may result in PR Products being shipped to, sold and dispensed to patients in the Territory (such sale or dispensing in the Territory referred to as an “Inter-Territory Sale”), and (ii) certain sales of PR Product outside the Territory by Santarus to Persons purchasing PR Products under the FSS or the United States Government, or to any of its subdivisions (whether or not purchasing under the FSS), may result in PR Product being shipped to military bases and other government installations that are in the Territory, and in each case such sales will not constitute a breach of this Agreement. With respect to Inter-Territory Sales, for so long as royalties are payable to Santarus pursuant to Section 6.2, Santarus agrees to provide to GSK a credit against royalties on Net Sales due and payable to Santarus under Section 6.2 in an amount equal to [***]. In the event that royalties are no longer payable to Santarus hereunder, Santarus shall promptly pay to GSK, rather than giving GSK a credit for, the amounts calculated as described above. On a monthly basis, GSK shall provide Santarus with written evidence establishing the applicable Inter-Territory Sales (in...
Sample 1
Santarus. Santarus shall maintain self insurance or comprehensive general liability insurance (“CGL”), including broad form contractual liability, in an amount of at least [***] Dollars ($[***]) and product liability coverage in an amount of at least [***] Dollars ($[***]) for bodily injury and property damage. Santarus shall maintain such insurance during the Term and thereafter for a period of [***]. Santarus shall give GSK at least [***] days notice of any cancellation or termination of such insurance. Santarus will furnish to GSK a certificate of insurance evidencing such coverage (or evidence reasonably acceptable to GSK of Santarus level of self-insurance) as of the Effective Date and upon reasonable request by GSK at any time thereafter.
Sample 1
AutoNDA by SimpleDocs
Santarus. Santarus shall maintain self insurance or comprehensive general liability insurance (“CGL”), including broad form contractual liability, in an amount of at least [***] Dollars (U.S. $[***]) and product liability coverage in an amount of at least [***] U.S. Dollars (U.S. $[***]) for bodily injury and property damage. Santarus shall maintain such insurance during the Term and thereafter for a period of [***]. Santarus shall give GSK at least [***] notice of any cancellation or termination of such insurance. Santarus will furnish to GSK a certificate of insurance evidencing such coverage (or evidence reasonably acceptable to GSK of Santarus level of self-insurance) as of the Effective Date and upon reasonable request by GSK at any time thereafter.
Sample 1

Related to Santarus

  • Baxter and Nexell shall cooperate in any action taken by a third party solely involving a nullity action, opposition, reexamination or any other action taken by such third party alleging the invalidity or unenforceability of any Licensed Intellectual Property. Both parties agree to share equally in the cost of the defense of such Licensed Intellectual Property.

  • Licensee Licensee represents and warrants that:

  • Licensor any Person from whom a Grantor obtains the right to use any Intellectual Property. Lien: any Person’s interest in Property securing an obligation owed to, or a claim by, such Person, whether such interest is based on common law, statute or contract, including liens, security interests, pledges, hypothecations, statutory trusts, reservations, exceptions, encroachments, easements, rights-of-way, covenants, conditions, restrictions, leases, and other title exceptions and encumbrances affecting Property. Lien Waiver: an agreement, in form and substance satisfactory to Collateral Agent, by which (a) for any material Collateral located on leased premises, the lessor waives or subordinates any Lien it may have on the Collateral, and agrees to permit Collateral Agent to enter upon the premises and remove the Collateral or to use the premises to store or dispose of the Collateral; (b) for any Collateral held by a warehouseman, processor, shipper, customs broker or freight forwarder, such Person waives or subordinates any Lien it may have on the Collateral, agrees to hold any Documents in its possession relating to the Collateral as agent for Collateral Agent, and agrees to deliver the Collateral to Collateral Agent upon request; (c) for any Collateral held by a repairman, mechanic or bailee, such Person acknowledges Collateral Agent’s Lien, waives or subordinates any Lien it may have on the Collateral, and agrees to deliver the Collateral to Collateral Agent upon request; and (d) for any Collateral subject to a Licensor’s Intellectual Property rights, the Licensor grants to Collateral Agent the right, vis-à-vis such Licensor, to enforce Collateral Agent’s Liens with respect to the Collateral, including the right to dispose of it with the benefit of the Intellectual Property, whether or not a default exists under any applicable License.

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • Distributor The Distributor represents and warrants that: (i) the Distributor is a limited partnership duly organized and in good standing under New York law; (ii) the Distributor is registered as a broker-dealer under federal and applicable state securities laws and is a member of the NASD; and (iii) the Distributor is registered as an investment adviser under federal securities laws.

  • Sublicensee The term “

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Licensed Territory Worldwide NIH Patent License Agreement—Exclusive APPENDIX C – ROYALTIES Royalties:

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • AMD AMD shall keep records in sufficient detail to enable FoundryCo to determine that AMD has complied with its second sourcing limitations in Section 2.1(b) and its GPU Product volume sourcing commitments in Section 2.1(c). AMD shall permit said records to be inspected, at FoundryCo’s expense, upon reasonable advance notice, during regular business hours by an independent auditor selected by FoundryCo and approved by AMD, which approval shall not be unreasonably withheld. The audit shall be for the purpose of verifying that AMD has complied with its second source restrictions in Section 2.1(b) and its GPU Product sourcing commitments in Section 2.1(c). Inspections conducted under this Section 8.1(b) shall be at FoundryCo’s expense, unless AMD has a non-compliance variance adverse to FoundryCo of [****] percent ([****]%) or more of (i) the relevant [****] percent ([****]%) second source restriction or (ii) the GPU Minimum Percentage for the applicable audited period, in which case AMD shall bear the reasonable expenses of such audit.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!